Sumitomo Mitsui Trust Group’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Sumitomo Mitsui Trust Group’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-543,189	Closed	-$62.8M	–	1164
2023 Q3	$62.8M	Sell	543,189 -8,817	-2%	-$947K	0.05%	374
2023 Q2	$56.8M	Sell	552,006 -79,862	-13%	-$8.43M	0.04%	432
2023 Q1	$69M	Sell	631,868 -19,621	-3%	-$2.17M	0.05%	395
2022 Q4	$74.1M	Buy	651,489 +2,262	+0.3%	+$188K	0.06%	377
2022 Q3	$40.2M	Buy	649,227 +2,838	+0.4%	+$198K	0.03%	543
2022 Q2	$51.6M	Buy	646,389 +31,038	+5%	+$2.94M	0.04%	499
2022 Q1	$64.7M	Buy	+615,351	New	+$60M	0.04%	453

Other funds holding HZNP

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Blue Trust Inc Alpharetta, Georgia $9.51B AUM 13.02% 1-Year Est. Return

VWA

Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return

FSWA

Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Sumitomo Mitsui Trust Group's HZNP Position: Q4 2023 in Review

Sumitomo Mitsui Trust Group sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 543,189 shares — an estimated $62.8M sold.

Sumitomo Mitsui Trust Group first reported a position in HZNP in Q1 2022 and held it in 7 quarters. The position peaked at $74.1M in Q4 2022. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

Sumitomo Mitsui Trust Group reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
Sumitomo Mitsui Trust Group sold 543,189 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $62.8M.
Sumitomo Mitsui Trust Group first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2022 and held it in 7 quarters.
Sumitomo Mitsui Trust Group's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $74.1M in Q4 2022.
6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Sumitomo Mitsui Trust Group's 13F filing for Q4 2023, filed 30 Jan 2024.